67496-96-2

Upstream product

• 1501-98-0 1-adamantylmethylamine hydrochloride 
• 17768-41-1 adamantylmethylamine 
• 61040-00-4 1-bromo-3-(aminomethyl)adamantane 

Downstream Products

• 400749-85-1 1-(3,4-xylyl)-3-aminomethyladamantane 
• 136611-70-6 1-(3-sulfo-4-hydroxyphenyl)-3-aminomethyladamantane 
• 136611-67-1 1-(3,4-dichlorophenyl)-3-aminomethyladamantane hydrosulfate 
• 136611-71-7 1-(4-tolyl)-3-aminomethyladamantane methanesulfonate 
• 142230-14-6 C-(3-{2-Methoxy-5-[(5Z,10Z,14Z,19Z)-10,15,20-tris-(4-methoxy-phenyl)-porphyrin-5-yl]-phenyl}-adamantan-1-yl)-methylamine 
• 142230-15-7 C-(3-{5-[(1Z,4Z,9Z,15Z)-15-[3-(3-Aminomethyl-adamantan-1-yl)-4-methoxy-phenyl]-10,20-bis-(4-methoxy-phenyl)-porphyrin-5-yl]-2-methoxy-phenyl}-adamantan-1-yl)-methylamine 
• 136611-69-3 1-(4-sulfophenyl)-3-aminomethyladamantane 
• 142230-17-9 C-{3-[4-((5Z,10Z,14Z,19Z)-10,15,20-Triphenyl-porphyrin-5-yl)-phenyl]-adamantan-1-yl}-methylamine 
• 142230-21-5 N-(3-{5-[(1Z,4Z,9Z,15Z)-15-{3-[3-(Acetylamino-methyl)-adamantan-1-yl]-4-methoxy-phenyl}-10,20-bis-(4-methoxy-phenyl)-porphyrin-5-yl]-2-methoxy-phenyl}-adamantan-1-ylmethyl)-acetamide 

Relevant academic research and scientific papers

8-Azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonists

The invention provides novel 8-azabicyclo[3.2.1]octane compounds of formula (I): wherein R1, R2, R3, A, and G are defined in the specification, or a pharmaceutically-acceptable salt or solvate thereof, that are antagonists at the mu opioid receptor. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat conditions associated with mu opioid receptor activity, and processes and intermediates useful for preparing such compounds.

NEW ADAMANTANE DERIVATIVES AS DIPEPTIDYL, PEPTIDASE IV INHIBITORS, PROCESSES FOR THEIR PREPARATION, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM

The present invention relates to dipeptidyl peptidase IV (DPP-IV) inhibitors of the formula (A): wherein R1, R2, Y, and n are as defined herein, pharmaceutical compositions containing the same, processes for their preparation, and methods for treating disorders mediated by DPP-IV inhibition, such as diabetes, especially Type II diabetes, with them.